AnalystsThomas SmithThomas Smith's Stock Forecasts
AnalystsThomas Smith
Sectors:
Industries:
Analyst Ranking
Top 7%
#343 out of 4867 analysts
Average Return
+28.53%
Win Rate
35%24 out of 69
Risk vs Reward
Poor
Good
Thomas Smith's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Viking Therapeutics IncVKTX | +710.33% | $2.42 | $19.61 | 2022-04-27 - 2023-04-27 | Buy |
Moonlake ImmunotherapeuticsMLTX | +499.03% | $9.27 | $55.53 | 2022-08-24 - 2023-08-24 | Buy |
89bio IncETNB | +488.18% | $3.30 | $19.41 | 2022-07-10 - 2023-07-10 | Buy |
Prometheus Biosciences IncRXDX | +313.14% | $48.39 | $199.92 | 2022-08-11 - 2023-06-15 | Buy |
89bio IncETNB | +293.00% | $4.14 | $16.27 | 2022-03-24 - 2023-03-24 | Buy |
Thomas Smith Analyst Color
Get additional color on Thomas Smith's coverage of popular stocks
Thomas Smith's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Equillium IncEQ | 4 | Hold | $1.00 | +118.34% | Downgrades | a month ago |
Q32 Bio IncQTTB | 2 | Hold | $9.00 | +434.12% | Downgrades | 5 months ago |
Aclaris Therapeutics IncACRS | 3 | Buy | $7.00 | +414.71% | Upgrades | 5 months ago |
Alumis IncALMS | 1 | Buy | $29.00 | +603.88% | Initiates Coverage On | 9 months ago |
Cartesian Therapeutics IncRNAC | 1 | Buy | $39.00 | N/A | Initiates Coverage On | a year ago |
Alpine Immune Sciences IncALPN | 2 | Hold | $65.00 | N/A | Downgrades | a year ago |
Sagimet Biosciences IncSGMT | 1 | Buy | $26.00 | N/A | Initiates Coverage On | a year ago |
Rapt Therapeutics IncRAPT | 2 | Hold | $10.00 | N/A | Downgrades | a year ago |
Cymabay Therapeutics IncCBAY | 2 | Hold | $32.50 | N/A | Downgrades | a year ago |
Abivax SaABVX | 1 | Buy | $20.00 | N/A | Initiates Coverage On | a year ago |
Vectivbio Holding AgVECT | 3 | Hold | $17.00 | N/A | Downgrades | 2 years ago |
Morphic Holding IncMORF | 1 | Buy | $56.00 | N/A | Maintains | 2 years ago |
Argenx SeARGX | 3 | Buy | $435.00 | N/A | Maintains | 2 years ago |
Intercept Pharmaceuticals IncICPT | 4 | Hold | $18.00 | N/A | Maintains | 2 years ago |
Disc Medicine IncIRON | 1 | Buy | $36.00 | N/A | Initiates Coverage On | 2 years ago |
Connect Biopharma Holdings LtdCNTB | 4 | Buy | $7.00 | N/A | Maintains | 2 years ago |
Immunovant IncIMVT | 3 | Buy | $21.00 | N/A | Maintains | 2 years ago |
Viridian Therapeutics IncVRDN | 2 | Buy | $45.00 | N/A | Maintains | 2 years ago |
Trevi Therapeutics IncTRVI | 1 | Buy | $6.00 | N/A | Initiates Coverage On | 2 years ago |
Provention Bio IncPRVB | 2 | Buy | $19.00 | N/A | Maintains | 2 years ago |
Landos Biopharma IncLABP | 4 | Hold | $20.00 | N/A | Maintains | 2 years ago |
Mannkind CorpMNKD | 2 | Buy | $6.00 | N/A | Maintains | 2 years ago |
Immunic IncIMUX | 3 | Hold | $5.00 | N/A | Downgrades | 3 years ago |
Dice Therapeutics IncDICE | 1 | Buy | $77.00 | N/A | Maintains | 3 years ago |
Moonlake ImmunotherapeuticsMLTX | 1 | Buy | $17.00 | N/A | Initiates Coverage On | 3 years ago |
Prometheus Biosciences IncRXDX | 5 | Buy | $60.00 | N/A | Maintains | 3 years ago |
Celldex Therapeutics IncCLDX | 2 | Buy | $64.00 | N/A | Maintains | 3 years ago |
Puretech Health PLCPRTC | 5 | Buy | $70.00 | N/A | Maintains | 3 years ago |
Axcella Health IncAXLA | 5 | Buy | $150.00 | N/A | Maintains | 3 years ago |
89bio IncETNB | 3 | Buy | $29.00 | N/A | Maintains | 3 years ago |
Eledon Pharmaceuticals IncELDN | 3 | Buy | $26.00 | N/A | Maintains | 3 years ago |
Allakos IncALLK | 3 | Hold | $12.00 | N/A | Maintains | 3 years ago |
Viking Therapeutics IncVKTX | 1 | Buy | $12.00 | N/A | Maintains | 3 years ago |
Genfit SaGNFT | 2 | Buy | $10.00 | N/A | Maintains | 3 years ago |
Galecto IncGLTO | 2 | Buy | $400.00 | N/A | Maintains | 4 years ago |
Keros Therapeutics IncKROS | 1 | Buy | $42.00 | N/A | Initiates Coverage On | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.